Alembic Crosses $250m Annual Sales In US

Company Plans 10 New Launches In First Half Of FY21

Growth
Alembic sees unprecedented growth in its US business • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

More from Earnings

More from Business